samalizumab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 464386468

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu/o

| target = CD200

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1073059-33-2

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 64EUX713G6

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D09961

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6542 | H=10086 | N=1702 | O=2102 | S=46

}}

Samalizumab is a humanized monoclonal antibody designed for oncology indications.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}} Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. {{cite journal | vauthors = Mahadevan D, Lanasa MC, Farber C, Pandey M, Whelden M, Faas SJ, Ulery T, Kukreja A, Li L, Bedrosian CL, Zhang X, Heffner LT | title = Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200 | journal = Journal for Immunotherapy of Cancer | volume = 7 | issue = 1 | pages = 227 | date = August 2019 | doi = 10.1186/s40425-019-0710-1 | doi-access = free | pmid = 31443741 | pmc = 6708181 | hdl = 10150/634601 | hdl-access = free }}

Samalizumab was developed by Alexion Pharmaceuticals.